Andrew Stephen Duncombe MA, MBBS, DM, FRCP, FRC

Dr. Andrew Duncombe achieved first-class honors at Oxford University and then studied clinical medicine at St Thomas’. Following general medical training in Oxford and London, Andrew obtained a Wellcome Trust Research Fellowship at the Royal Free Hospital which led to a doctoral thesis at Oxford University. Andrew completed training in hematology through rotations at St Thomas’, St George’s, and the Royal Marsden Hospital, London before taking up my current post at University Hospital Southampton in 1994. Andrew has practiced at Spire Southampton since 2001. As a lead consultant in clinical hematology from 1995 to 2001.

Andrew has been involved in extensive research into myeloproliferative disorders (disorders of the blood cells). As a core member of the National Cancer Research Institute's myeloproliferative disorders subgroup, Andrew has co-authored national guidelines for the management and treatment of the conditions of myelofibrosis and eosinophilia. Andrew has been involved in research with patients with myelofibrosis which has led to the discovery of gene mutations that help to explain why some people are predisposed to acquiring genetic mutations that lead to blood cancers. Andrew is also highly experienced in lymphoid as well as myeloid blood cancers and involved in clinical trials in these disorders.

Andrew has authored more than 100 original articles and published abstracts including first author publications in the New England Journal of Medicine, Lancet, and British Medical Journal. Andrew co-authored the first edition of the Oxford Handbook of Clinical Haematology and contributed entries on this topic to the British Medical Association Family Health Encyclopedia, which went on to become an international bestseller. While on sabbatical in 2016, Andrew was a visiting guest lecturer at the University of Western Australia, Perth, University of New South Wales, Sydney, University of Otago, NZ, and University of Auckland, NZ.